CD274 and gastric cancer: Hence, the results of our study indicate that, sintilimab stands out as the sole ICI demonstrated to be cost-effective for GC/GEJC regardless of the PD-L1 expression levels thus far, attributed to its favorable clinical outcomes and comparatively modest pricing.